Zymtronix has been selected as a semifinalist for the EPA-lead Transform Tox Testing Challenge. The challenge aims to revolutionize the current approaches used to evaluate the safety of chemicals and better protect human health by evaluating not only the chemicals but also their metabolites. Metabolites are the molecules resulting from the conversion of chemicals by biological systems, including detoxifying enzymes found in the human liver. “Zymtronix has a unique platform that can assemble synthetic enzymatic routes to mimic natural biological systems. We are excited to advance our universal enzyme immobilization platform toward metabolic enzymes and high-throughput screening” says Stéphane Corgié, CEO of Zymtronix.